Validation of a treadmill six-minute walk test protocol for the evaluation of patients with pulmonary arterial hypertension;Validação de um protocolo para o teste de caminhada de seis minutos em esteira para avaliação de pacientes com hipertensão arterial pulmonar

Jornal Brasileiro de Pneumologia

Volumn 35, Issue 5, 2009, Pages 423-430

  de Camargo, Viviane Moreira ^a   Martins, Barbara do Carmo dos Santos ^a   Jardim, Carlos ^a   Fernandes, Caio Julio Cesar ^a   Hovnanian, Andre ^a   Souza, Rogério ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Exercise test; Hemodynamics; Hypertension, pulmonary

Indexed keywords

NITRIC OXIDE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; COMPARATIVE STUDY; EXERCISE TEST; FEMALE; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; INHALATION; INSTRUMENTATION; KAPLAN MEIER METHOD; MALE; METHODOLOGY; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY HYPERTENSION; STANDARD; VALIDATION STUDY; WALKING;

ADULT; ANALYSIS OF VARIANCE; EXERCISE TEST; FEMALE; HEART CATHETERIZATION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INHALATION; KAPLAN-MEIER ESTIMATE; MALE; NITRIC OXIDE; WALKING;

EID: 67849127204     PISSN: 18063713     EISSN: 18063713     Source Type: Journal    
DOI: 10.1590/s1806-37132009000500006     Document Type: Article

References (20)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425-36.
2. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol. 2004;43(12 Suppl S):48S-55S.
3. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161(2 Pt 1):487-92.
4. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J. 2001;17(4):647-52.
5. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7.
6. Stevens D, Elpern E, Sharma K, Szidon P, Ankin M, Kesten S. Comparison of hallway and treadmill six-minute walk tests. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1540-3.
7. Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes Brasileiras para o Manejo da Hipertensão Pulmonar. J Bras Pneumol. 2005;31(Suppl 2):S1-S31.
8. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):5S-12S.
9. Costa EL, Jardim C, Bogossian HB, Amato MB, Carvalho CR, Souza R. Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria. Vascul Pharmacol. 2005;43(3):143-7.
10. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105-11.
11. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169(4):441-7.
12. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334(5):296-302.
13. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903. Erratum in: N Engl J Med. 2002;346(16):1258.
14. Lapa MS, Ferreira EV, Jardim C, Martins Bdo C, Arakaki JS, Souza R. Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of Sao Paulo [article in Portuguese]. Rev Assoc Med Bras. 2006;52(3):139-43.
15. Kloos H, Correa-Oliveira R, Oliveira Quites HF, Caetano Souza MC, Gazzinelli A. Socioeconomic studies of schistosomiasis in Brazil: a review. Acta Trop. 2008;108(2-3):194-201.
16. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57. Erratum in: N Engl J Med. 2006;354(22):2400-1.
17. Souza R, Jardim C, Martins B, Cortopassi F, Yaksic M, Rabelo R, et al. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr Med Res Opin. 2005;21(6):907-11.
18. Souza R, Martins BC, Jardim C, Cortopassi F, Fernandes CJ, Pulido T, et al. Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension. Int J Clin Pract. 2007;61(1):153-6.
19. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-9.
20. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve ́ P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-8.